Gutiérrez Julie F, Bajaj Komal, Klugman Susan D
Albert Einstein College of Medicine, Bronx, NY.
Rev Obstet Gynecol. 2013;6(1):e1-7.
In addition to causing developmental disability in future offspring, fragile X carrier status has important reproductive and mental health implications for the individual being tested. Accordingly, prenatal carrier screening and diagnosis using DNA-based molecular methods has become crucial in early detection, intervention, and family planning. Although the list of known genetic disorders is growing daily, controversy remains over who should be tested for fragile X. FMR1 gene mutations can result in inherited intellectual disability, infertility, and neurodegeneration syndromes that are encountered by clinicians in a variety of settings. Patients and clinicians are still largely unfamiliar with this disorder, its complicated inheritance, and its heterogeneous phenotype. Debate continues over who should be offered prenatal carrier screening. As more disease screening is offered, pretest counseling will become only more complex and clinicians will further struggle to balance the needs of the individual and allocation of public health resources.
除了会导致未来后代出现发育障碍外,脆性X携带者状态对接受检测的个体的生殖和心理健康也具有重要影响。因此,使用基于DNA的分子方法进行产前携带者筛查和诊断,对于早期检测、干预及计划生育而言已变得至关重要。尽管已知的遗传疾病清单每天都在增加,但对于谁应该接受脆性X检测仍存在争议。FMR1基因突变可导致遗传性智力残疾、不孕不育以及神经退行性综合征,临床医生在各种情况下都会遇到这些情况。患者和临床医生对这种疾病、其复杂的遗传方式以及异质性表型仍然大多不熟悉。关于应该为谁提供产前携带者筛查的争论仍在继续。随着提供的疾病筛查越来越多,检测前咨询将变得更加复杂,临床医生在平衡个体需求和公共卫生资源分配方面也将面临更大困难。